文献速递泌尿男性生殖肿瘤

2020年肌层浸润性和晚期膀胱癌的治疗

Treatment of muscle-invasive and advanced bladder cancer in 2020.
PubMed 文献 · CA Cancer J Clin · 2020-08-07

综述回顾了肌层浸润性和晚期膀胱癌的治疗历史,指出四十余年来以铂类化疗为主,近十年测序技术推动基因组特征解析,基于高突变负荷开展了免疫检查点抑制剂研究并在部分患者中显示持久缓解,同时靶向治疗如FGFR抑制剂和抗体药物偶联物得到开发。

要点

  • 晚期膀胱癌免疫检查点抑制剂已在部分患者中显示持久缓解并获批多个适应证。
  • FGFR抑制剂和抗体药物偶联物等靶向治疗基于常见分子靶点开发。
  • 分子特征解析正推动肌层浸润性膀胱癌治疗策略的优化研究。

核心结论

  • 晚期膀胱癌治疗格局正在改变,免疫检查点抑制剂和靶向治疗为部分患者带来新选择。

研究设计与样本

  • 综述,回顾肌层浸润性和晚期膀胱癌的管理历史、分子特征、治疗进展及未来方向。

主要发现

  • 基于高突变负荷,免疫检查点抑制剂在晚期膀胱癌中显示部分患者持久缓解。
  • FGFR抑制剂和抗体药物偶联物等靶向治疗已基于常见分子靶点开发。

临床怎么用

  • 分子特征解析有助于识别可能从免疫治疗或靶向治疗中获益的晚期膀胱癌患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle-invasive and advanced bladder cancer has primarily consisted of platinum-based chemotherapy. Over the past 10 years, innovations in sequencing technologies have led to rapid genomic characterization of bladder cancer, deepening our understanding of bladder cancer pathogenesis and exposing potential therapeutic vulnerabilities. On the basis of its high mutational burden, immune checkpoint inhibitors were investigated in advanced bladder cancer, revealing durable responses in a subset of patients. These agents are now approved for several indications and highlight the changing treatment landscape of advanced bladder cancer. In addition, commonly expressed molecular targets were leveraged to develop targeted therapies, such as fibroblast growth factor receptor inhibitors and antibody-drug conjugates. The molecular characterization of bladder cancer and the development of novel therapies also have stimulated investigations into optimizing treatment approaches for muscle-invasive bladder cancer. Herein, the authors review the history of muscle-invasive and advanced bladder cancer management, highlight the important molecular characteristics of bladder cancer, describe the major advances in treatment, and offer future directions for therapeutic development.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Patel VG, Oh WK, Galsky MD, et al. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020. PMID: 32767764. doi:10.3322/caac.21631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。